The new Zepbound vs Wegovy heart study, first published November 10, 2026, does not show that either medicine protects the heart better. Its main comparison found no statistically clear difference in serious events. Results depended on how the records were analyzed. An unclear result doesn't prove the drugs are equal, either.
Zepbound contains tirzepatide. Wegovy contains semaglutide. The broader Zepbound vs Wegovy comparison explains their differences beyond this heart study.
Zepbound vs Wegovy heart: what happened
As of November 20, 2026, the day this article was written, a study first published November 10 in Diabetes, Obesity and Metabolism adds a comparison from everyday care. Gwen Aubrac and colleagues used claims data, meaning insurance billing records, from Komodo Health.
They studied people with atherosclerotic cardiovascular disease, meaning plaque buildup in arteries, and overweight or obesity, without diabetes. Their BMI, a measure relating weight to height, was at least 27.
| What the researchers followed | Study count |
|---|---|
| People starting Wegovy | 6,817 |
| People starting Zepbound | 8,526 |
| Serious events in the combined main outcome | 366 |
| Longest possible follow-up | 12 months |
Average follow-up was about seven months. That is short for studying heart disease.
The main outcome combined heart attacks, strokes, artery-opening procedures and deaths from any cause. It also counted hospital stays for heart failure, when the heart cannot fill or pump well. Admissions for unstable angina, worsening chest pain from restricted blood flow, counted too. Deaths were not limited to heart causes because those details weren't available.
The Robert Wood Johnson Foundation and American Heart Association funded the work. Coauthor Robert Platt disclosed unrelated consulting for Merck, Veracity and Daiichi Sankyo. The other authors declared no conflicts.
What the main number means
A hazard ratio compares how quickly events occurred in the two groups. Here it was 1.21 for semaglutide compared with tirzepatide, with tirzepatide as the reference group.
The 95% confidence interval, a range describing uncertainty around that estimate, was 0.99 to 1.51. Because it includes 1, the data are compatible with no difference.
The estimate leaned toward more events with semaglutide, but it was too uncertain to establish a difference. It does not mean 21 extra people in every 100 had a heart attack. And an unclear result cannot establish that the medicines have equal effects.
What this means for a prescription
The established heart evidence still matters. In SELECT, published in the New England Journal of Medicine in 2023, researchers assigned treatment by chance. They compared semaglutide with placebo, a look-alike treatment without the medicine, in people with existing heart disease and no diabetes.
SELECT found fewer major heart events with semaglutide. It did not compare Wegovy with Zepbound. The SELECT results guide explains its outcomes and side effects.
As of November 20, 2026, the day this article was written, the FDA-posted Wegovy label reads “Revised: 06/2026.” It includes reducing heart-related death, nonfatal heart attack and nonfatal stroke in adults with established cardiovascular disease and either overweight or obesity. An indication is a specific use on a medicine's label.
As of November 20, 2026, the day this article was written, Zepbound's current label reads “Revised: 11/2026” and carries no cardiovascular indication. It lists weight reduction and long-term maintenance, plus moderate to severe obstructive sleep apnea in adults with obesity. Sleep apnea means repeated interruptions in breathing during sleep. The FDA-posted Zepbound label, revised August 2026, lists the same two uses.
The other major tirzepatide heart trial answered a different question. SURPASS-CVOT, published in NEJM in 2025, compared tirzepatide with dulaglutide, another diabetes medicine. Participants had type 2 diabetes, a condition that keeps blood sugar too high. Its results and limits cannot settle this comparison in people without diabetes.
What this result does not establish
This was an observational study: patients and prescribers chose the medicine, rather than researchers assigning it by chance. Accounting for recorded differences helps, but it cannot remove differences the records don't capture. Blood pressure, smoking and other important factors were missing.
Sensitivity analyses, checks using different reasonable methods, kept the main estimates pointing in the same direction. Some reached statistical significance when researchers kept people in their starting treatment group or left out the first 90 days. Including diabetes brands or counting outpatient claims also produced significant results. The conclusion therefore depended on how the comparison was made.
Those checks are not separate trials. Short follow-up and relatively few events also leave long-term differences uncertain. There were too few deaths to estimate a separate death-risk comparison.
Safety instructions still stand
As of November 20, 2026, the day this article was written, the FDA's November 9 safety communication requires new warnings across GLP-1 medicines. These medicines act on a gut-hormone signal involved in appetite and blood sugar. The warning concerns NAION, a rare loss of blood flow to the nerve carrying sight signals, which can cause permanent vision loss.
FDA says to contact a health care professional right away for sudden painless sight loss, blurred or missing vision, or changes in color or sharpness. It tells clinicians to consider stopping treatment if NAION develops, unless the benefits clearly outweigh the risk. A heart-study headline does not override those instructions.
Where a compounded prescription fits
Tirzepatide and semaglutide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications, which are different from an FDA-approved product: the formulations offered here are not FDA-approved.
Compounding means a pharmacy prepares medication for a prescription. The FDA explains that it does not verify these preparations' safety, effectiveness or quality before marketing. A study of the brands does not establish matching heart outcomes for a compounded preparation.
A licensed provider may still prescribe — that decision is between you and your doctor.
What to watch next
A longer randomized comparison in people without diabetes would give a firmer answer. It would need enough heart events to make the comparison meaningful, alongside clear reporting of side effects and treatment stops.
For someone already taking either medicine, this study alone does not support switching. That is a prescriber conversation about the heart diagnosis, other medicines, response so far and tolerability, meaning how manageable the side effects are.
At Promise, a licensed U.S. provider reviews every request, and not everyone qualifies. The prescriber sets the actual dose and any change in treatment.





